Drugs / retinal pigment epithelium
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03046407 | Sep 2017 → Jan 2019 | dry age related macular degeneration | Chinese Academy of Sciences | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | retinal pigment epithelium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03046407 ↗ |
| Modality | Cell therapy | “retinal pigment epithelium derived from human embryonic stem cells” NCT03046407 ↗ |
| Route | Other | “into subretinal space” NCT03046407 ↗ |